Atlas Trials

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Clinical trial NCT03820180 · COMPLETED

Trial details

NCT number
NCT03820180
Sponsor
Respirent Pharmaceuticals Co Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2019-01-23
Primary completion
2019-02-12
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.